Hematologic Malignancies Articles

Frontline Obinutuzumab Recommended for EU Approval for Follicular Lymphoma
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of obinutuzumab in the frontline setting for the treatment of patients with follicular lymphoma.
Midostaurin Recommended for EU Approval for AML
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of midostaurin to treat adults with newly diagnosed acute myeloid leukemia who are FLT3 mutation-positive.
Emerging Agents Poised to Transform AML Landscape
Jeffrey E. Lancet, MD, discusses new discoveries in the treatment of AML and challenges that remain in improving patient outcomes.
Proteasome Inhibitors Paving Promising Path for Myeloma Treatment
Kenneth H. Shain, MD, discusses the emergence of proteasome inhibitors in multiple myeloma and whether these agents will be best used as monotherapy or in combination regimens.
Bendamustine Plus Rituximab Maintains Frontline PFS Benefit in MCL, iNHL After 5 Years
Five-year follow-up from the BRIGHT study confirmed that bendamustine plus rituximab is associated with improved progression-free survival compared with R-CHOP or R-CVP in patients with mantle cell lymphoma or indolent non-Hodgkin lymphoma.
Myeloma Trial Explores Optimal Induction, Maintenance Regimens
Two combination regimens anchored by different proteasome inhibitors are being compared in a national clinical trial for patients with newly diagnosed symptomatic multiple myeloma that also seeks to evaluate the ideal duration of lenalidomide (Revlimid) maintenance therapy.
Amgen has announced that it has submitted supplemental New Drug Applications (sNDA) in the United States and Europe based on data from 2 phase III studies showing carfilzomib (Kyprolis) improves overall survival (OS) for patients with relapsed/refractory multiple myeloma.
Predictive Factors Found for Treatment With FCO in CLL
A mutation on the NOTCH1 gene was shown to be an independent predictive factor for the reduced efficacy of ofatumumab (Arzerra), a human monoclonal CD20 antibody, in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Obinutuzumab and Bendamustine Combo Shows Encouraging Activity in Upfront CLL
The anti-CD20 monoclonal antibody obinutuzumab (Gazyva) combined with bendamustine (Treanda; BG) in the frontline setting for patients with chronic lymphocytic leukemia was found to induce high rates of complete response and minimal residual disease negativity with no unexpected safety signals, according to results from a phase II open-label, multicenter study.
Carfilzomib Combo Extends Survival for Myeloma in Final ASPIRE Analysis
The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone reduced the risk of death by 21% compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma.
Publication Bottom Border
Border Publication